Recruiting Clinical Trials

Displaying 41 - 50 of 227 result(s)
Study Title Condition Phase Location
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation Chronic Myelogenous Leukemia - Chronic Phase Phase 3
  • Country: 
    United States
A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory Type 2 Spinal Muscular Atrophy Phase 3
  • Country: 
    United States
  • Country: 
    China
  • Country: 
    Denmark
  • Country: 
A Phase Ib/II, Open Label Study of Siremadlin Monotherapy and in Combination With Donor Lymphocyte Infusion as a Treatment for Patients With Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplantation Who Are in Complete Remission But at High Ri ... Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation Phase 1, Phase 2
  • Country: 
    Israel
  • Country: 
    Italy
  • Country: 
    Spain
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular ... CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases Phase 2
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Canada
  • Country: 
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study Multiple Sclerosis Not Given
  • Country: 
    United States
A Phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Pa ... Acute Myeloid Leukemia Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Hong Kong
  • Country: 
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas Metastatic Uveal Melanoma Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    France
  • Country: 
Secondary Use of Data Study Characterizing Kesimpta (Ofatumumab) Onboarding and Utilization in RMS Patients Using MSGo, With a Non-interventional Primary Use of Data Sub-study Comparing Patient Reported Outcomes Relative to Clinical Outcomes (EAFToS) Relapsing Multiple Sclerosis Not Given
  • Country: 
    Australia
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS) Multiple Sclerosis Not Given
  • Country: 
    Switzerland
A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an "Inclisiran First" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (≥70 mg/dL) D ... Atherosclerotic Cardiovascular Disease Phase 3
  • Country: 
    United States